COMMUNIQUÉ DE PRESSE
News
-
-
COMMUNIQUÉ DE PRESSE
Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic
Mainz Biomed partners with Trusted Health Advisors to support U.S. go-to-market strategy for next generation early colorectal cancer diagnostic -
-
COMMUNIQUÉ DE PRESSE
New Survey Finds More Than Half of Past U.S. Colonoscopy Patients Wish They Had Known More Information About Colonoscopies Including Prep Medication Options and How To Prepare for the Procedure
Salix Pharmaceuticals releases findings from first colonoscopy awareness survey, revealing insights on patient perspectives, barriers, and healthcare provider recommendations -
-
COMMUNIQUÉ DE PRESSE
Universal EV Chargers Secures Major Federal Funding Boost for Tennessee's Electric Vehicle Infrastructure
Universal EV Chargers secures over $21 million federal funding from Tennessee for EV charging infrastructure development, highlighting commitment to sustainable transportation -
COMMUNIQUÉ DE PRESSE
Bone Health Technologies Secures $5 Million in Funding to Transform Osteopenia Care
Bone Health Technologies (BHT) closes oversubscribed $5 million financing round with new investors, including Terumo Medical, to advance Osteoboost wearable vibration device for postmenopausal women's bone health -
COMMUNIQUÉ DE PRESSE
Photon and Modulate Unite to Transform Online Gaming with Next-Gen Voice Moderation Integration
Modulate and Photon announce strategic partnership integrating prosocial voice moderation technology, ToxMod, with leading multiplayer and voice service for enhanced user experience and compliance with global regulations -
COMMUNIQUÉ DE PRESSE
Xitoring Launches Cloud Monitoring for Microsoft Azure VMs
Xitoring integrates with Microsoft Azure to provide enhanced monitoring capabilities for virtual machines running Linux and Windows operating systems, offering users real-time visibility and control over their cloud infrastructure -
COMMUNIQUÉ DE PRESSE
FSD Pharma Presents Positive Results on First-In-Human Phase-1 study of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 Forum
FSD Pharma announces positive results of Lucid-21-302 in Phase-1 clinical study for MS treatment at ACTRIMS 2024 Forum. The presentation covered drug safety, absorption levels, and neuroprotective effects
